Covered recipient · General Payments record
RAKESH C PATEL
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$4,813.44
185 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,823.17 | 176 |
| Travel and Lodging | $1,969.27 | 7 |
| Consulting Fee | $20.00 | 1 |
| Education | $1.00 | 1 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| UCB Biosciences Inc. | $1,508.79 | 9 |
| Horizon Therapeutics plc | $1,143.54 | 12 |
| Amgen Inc. | $462.01 | 39 |
| Lilly USA, LLC | $320.93 | 20 |
| Novartis Pharmaceuticals Corporation | $159.10 | 12 |
| UCB, Inc. | $153.05 | 24 |
| Genentech USA, Inc. | $142.58 | 9 |
| PFIZER INC. | $142.43 | 13 |
| E.R. Squibb & Sons, L.L.C. | $129.78 | 13 |
| Sun Pharmaceutical Industries Inc. | $124.37 | 1 |
| AbbVie, Inc. | $118.53 | 7 |
| Regeneron Healthcare Solutions, Inc. | $88.20 | 5 |
| Janssen Biotech, Inc. | $57.91 | 4 |
| GlaxoSmithKline, LLC. | $50.98 | 3 |
| Radius Health, Inc. | $49.38 | 3 |
| Celgene Corporation | $46.06 | 2 |
| Hikma Pharmaceuticals USA | $25.94 | 2 |
| Vertical Pharmaceuticals, LLC | $24.64 | 2 |
| FIDIA PHARMA USA INC. | $21.01 | 2 |
| Merck Sharp & Dohme Corporation | $17.76 | 1 |
| Sebela Pharmaceuticals Inc. | $14.73 | 1 |
| Circassia Pharmaceuticals Inc | $11.72 | 1 |
Page 4 of 4; records 151–185 of 185 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RAKESH C PATEL
NPI 1295712305 · CMS profile ID 148800
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
SALISBURY, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 4; records 151–185 of 185 matching records. This page contains 35 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1295712305?year=2019&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RAKESH C PATEL, NPI 1295712305, CMS profile ID 148800. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–185 of 185 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295712305?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). RAKESH C PATEL, NPI 1295712305, CMS profile ID 148800. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–185 of 185 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295712305?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- RAKESH C PATEL, NPI 1295712305, CMS profile ID 148800, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–185 of 185 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1295712305?year=2019&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
185 matching records · $4,813.44 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–185 of 185.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Horizon Therapeutics plc | $14.61 | 03/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691465427 | CMS |
| Novartis Pharmaceuticals Corporation | $20.89 | 03/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659905291 | CMS |
| Lilly USA, LLC | $12.03 | 03/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658091513 | CMS |
| E.R. Squibb & Sons, L.L.C. | $13.86 | 03/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651236975 | CMS |
| Amgen Inc. | $11.86 | 03/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662895987 | CMS |
| PFIZER INC. | $4.66 | 03/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672124699 | CMS |
| Amgen Inc. | $16.05 | 03/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662895971 | CMS |
| UCB, Inc. | $20.42 | 03/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688262109 | CMS |
| GlaxoSmithKline, LLC. | $20.00 | 03/01/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670655267 | CMS |
| Janssen Biotech, Inc. | $13.97 | 02/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658636143 | CMS |
| PFIZER INC. | $9.82 | 02/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672124625 | CMS |
| PFIZER INC. | $6.13 | 02/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672124691 | CMS |
| Radius Health, Inc. | $16.82 | 02/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 683933223 | CMS |
| Amgen Inc. | $4.26 | 02/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662895985 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.81 | 02/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651236963 | CMS |
| Genentech USA, Inc. | $14.60 | 02/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681266189 | CMS |
| Amgen Inc. | $17.54 | 02/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662895981 | CMS |
| Amgen Inc. | $11.71 | 02/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662895979 | CMS |
| UCB, Inc. | $8.20 | 02/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688250355 | CMS |
| UCB, Inc. | $5.80 | 02/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688255383 | CMS |
| UCB, Inc. | $2.04 | 02/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688350419 | CMS |
| Lilly USA, LLC | $5.60 | 01/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658084989 | CMS |
| PFIZER INC. | $14.60 | 01/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671874813 | CMS |
| E.R. Squibb & Sons, L.L.C. | $6.61 | 01/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651236961 | CMS |
| Novartis Pharmaceuticals Corporation | $18.62 | 01/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659905289 | CMS |
| Genentech USA, Inc. | $15.09 | 01/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681234837 | CMS |
| Horizon Therapeutics plc | $11.15 | 01/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691465423 | CMS |
| Radius Health, Inc. | $17.70 | 01/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 683933215 | CMS |
| Lilly USA, LLC | $19.31 | 01/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658099245 | CMS |
| Circassia Pharmaceuticals Inc | $11.72 | 01/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 660218629 | CMS |
| Amgen Inc. | $15.82 | 01/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662895977 | CMS |
| Hikma Pharmaceuticals USA | $14.73 | 01/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688414113 | CMS |
| Sebela Pharmaceuticals Inc. | $14.73 | 01/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703870953 | CMS |
| UCB, Inc. | $1.64 | 01/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688247475 | CMS |
| UCB, Inc. | $7.02 | 01/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688380821 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $110.00 | 1 |
| PY2025 | Principal investigator | $779,511.69 | 85 |
| PY2024 | Recipient | $25,580.68 | 3 |
| PY2024 | Principal investigator | $400,796.41 | 71 |
| PY2023 | Recipient | $1,310.83 | 9 |
| PY2023 | Principal investigator | $403,240.88 | 51 |
| PY2022 | Recipient | $195.00 | 1 |
| PY2022 | Principal investigator | $273,585.82 | 37 |
| PY2021 | Principal investigator | $536,740.44 | 76 |
| PY2020 | Recipient | $223.50 | 2 |
| PY2020 | Principal investigator | $670,480.33 | 93 |
| PY2019 | Principal investigator | $931,144.93 | 140 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
86 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $3,500.00 | 12/22/2025 | Non-covered Recipient Entity ON-SITE CLINICAL SOLUTIONS, LLC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175371969 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,166.00 | 11/28/2025 | Non-covered Recipient Entity ON-SITE CLINICAL SOLUTIONS, LLC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175371914 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,908.00 | 11/27/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175252511 |
| Principal investigator 1 | Janssen Research & Development, LLC | $52.00 | 11/27/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175252789 |
| Principal investigator 1 | ABBVIE INC. | $5,857.00 | 11/20/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202524964 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $18.55 | 11/20/2025 | Non-covered Recipient Entity Onsite Clinical Solutions | A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) | No dispute reported | 06/30/2026 | 1235994860 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 11/20/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175251088 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 11/20/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175252660 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,000.00 | 11/13/2025 | Non-covered Recipient Entity Onsite Clinical Solutions LLC | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) | No dispute reported | 06/30/2026 | 1220797417 |
| Principal investigator 1 | Janssen Research & Development, LLC | $166.00 | 11/10/2025 | Non-covered Recipient Entity ON-SITE CLINICAL SOLUTIONS, LLC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175371939 |
| Principal investigator 1 | ABBVIE INC. | $843.08 | 11/04/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202520911 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,000.00 | 10/27/2025 | Non-covered Recipient Entity ON-SITE CLINICAL SOLUTIONS, LLC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175371982 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $44,905.67 | 10/08/2025 | Non-covered Recipient Entity INTERSPOND, LLC | A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome | No dispute reported | 06/30/2026 | 1190299629 |
| Principal investigator 1 | Janssen Research & Development, LLC | $162.72 | 10/03/2025 | Non-covered Recipient Entity ON-SITE CLINICAL SOLUTIONS, LLC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175371976 |
| Principal investigator 1 | Eli Lilly and Company | $40.00 | 09/30/2025 | Non-covered Recipient Entity RHEUMATOLOGY CENTER OF HOUSTON | Not supplied | No dispute reported | 06/30/2026 | 1187887792 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,500.00 | 09/29/2025 | Non-covered Recipient Entity ON-SITE CLINICAL SOLUTIONS, LLC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175371921 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $116.60 | 09/24/2025 | Non-covered Recipient Entity Onsite Clinical Solutions | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) | No dispute reported | 06/30/2026 | 1220760151 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $119.88 | 09/24/2025 | Non-covered Recipient Entity Onsite Clinical Solutions | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) | No dispute reported | 06/30/2026 | 1220760153 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $511.00 | 09/24/2025 | Non-covered Recipient Entity Onsite Clinical Solutions | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) | No dispute reported | 06/30/2026 | 1220760155 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $131.10 | 09/24/2025 | Non-covered Recipient Entity Onsite Clinical Solutions | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) | No dispute reported | 06/30/2026 | 1220760157 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.56 | 09/24/2025 | Non-covered Recipient Entity Onsite Clinical Solutions | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) | No dispute reported | 06/30/2026 | 1220760159 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.56 | 09/24/2025 | Non-covered Recipient Entity Onsite Clinical Solutions | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) | No dispute reported | 06/30/2026 | 1220760161 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.56 | 09/24/2025 | Non-covered Recipient Entity Onsite Clinical Solutions | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) | No dispute reported | 06/30/2026 | 1220760163 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.56 | 09/24/2025 | Non-covered Recipient Entity Onsite Clinical Solutions | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) | No dispute reported | 06/30/2026 | 1220760165 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20.00 | 09/24/2025 | Non-covered Recipient Entity Onsite Clinical Solutions | A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD) | No dispute reported | 06/30/2026 | 1220760167 |
| Principal investigator 1 | Janssen Research & Development, LLC | $52.00 | 08/28/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175250492 |
| Principal investigator 1 | Janssen Research & Development, LLC | $52.00 | 08/28/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175250764 |
| Principal investigator 1 | Janssen Research & Development, LLC | $185.00 | 08/28/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175251178 |
| Principal investigator 1 | Janssen Research & Development, LLC | $185.00 | 08/28/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175252699 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,800.00 | 08/28/2025 | Non-covered Recipient Entity ON-SITE CLINICAL SOLUTIONS, LLC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175371931 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $26,029.00 | 08/18/2025 | Non-covered Recipient Entity Interspond, Llc | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment | No dispute reported | 06/30/2026 | 1235996541 |
| Principal investigator 1 | Amgen Inc. | $110.05 | 07/28/2025 | Non-covered Recipient Entity ROWAN DIAGNOSTIC CLINIC, PA | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246647480 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,800.00 | 07/28/2025 | Non-covered Recipient Entity ON-SITE CLINICAL SOLUTIONS, LLC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175371962 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,000.00 | 07/25/2025 | Non-covered Recipient Entity ON-SITE CLINICAL SOLUTIONS, LLC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175371945 |
| Principal investigator 1 | Amgen Inc. | $31,144.10 | 07/23/2025 | Non-covered Recipient Entity ONSITE CLINICAL SOLUTIONS,LLC | A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS) | No dispute reported | 06/30/2026 | 1246646025 |
| Principal investigator 1 | ABBVIE INC. | $5,857.00 | 07/09/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202497682 |
| Principal investigator 1 | Eli Lilly and Company | $9,762.00 | 07/08/2025 | Non-covered Recipient Entity ONSITE CLINICAL SOLUTIONS LLC | A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE | No dispute reported | 06/30/2026 | 1187886866 |
| Principal investigator 1 | Janssen Research & Development, LLC | $21,600.00 | 07/04/2025 | Non-covered Recipient Entity ON-SITE CLINICAL SOLUTIONS, LLC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175371955 |
| Principal investigator 1 | ABBVIE INC. | $843.08 | 07/02/2025 | Non-covered Recipient Entity ACCELLACARE US INC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202496523 |
| Principal investigator 1 | Janssen Research & Development, LLC | $185.00 | 06/30/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175249578 |
| Principal investigator 1 | Janssen Research & Development, LLC | $52.00 | 06/30/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175251096 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,674.00 | 06/30/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175251579 |
| Principal investigator 1 | Janssen Research & Development, LLC | $52.00 | 06/30/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175251611 |
| Principal investigator 1 | Janssen Research & Development, LLC | $52.00 | 05/28/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175249475 |
| Principal investigator 1 | Janssen Research & Development, LLC | $52.00 | 05/28/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175250689 |
| Principal investigator 1 | Janssen Research & Development, LLC | $185.00 | 05/28/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175252116 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,156.00 | 05/28/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175252844 |
| Principal investigator 1 | Janssen Research & Development, LLC | $300.00 | 05/28/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175252853 |
| Principal investigator 1 | Janssen Research & Development, LLC | $52.00 | 05/28/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175252972 |
| Principal investigator 1 | Janssen Research & Development, LLC | $185.00 | 05/28/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175253034 |
| Recipient | Eli Lilly and Company | $110.00 | 04/04/2025 | Covered Recipient Physician | AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3871801 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187872681 |
| Principal investigator 1 | Amgen Inc. | $280,799.24 | 04/02/2025 | Non-covered Recipient Entity INTERSPOND LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246642874 |
| Principal investigator 1 | ABBVIE INC. | $7,737.68 | 03/07/2025 | Non-covered Recipient Entity ACCELLACARE US INC | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202460824 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 03/07/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175250340 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 03/07/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175252741 |
| Principal investigator 1 | Eli Lilly and Company | $3,600.00 | 03/05/2025 | Non-covered Recipient Entity ONSITE CLINICAL SOLUTIONS LLC | TALTZ PSA OBSERVATIONAL STUDY | No dispute reported | 06/30/2026 | 1187889888 |
| Principal investigator 1 | Janssen Research & Development, LLC | $52.00 | 02/27/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175251330 |
| Principal investigator 1 | Janssen Research & Development, LLC | $185.00 | 02/27/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175251564 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,674.00 | 02/27/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175251663 |
| Principal investigator 1 | Janssen Research & Development, LLC | $52.00 | 02/27/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175252349 |
| Principal investigator 1 | Eli Lilly and Company | $10,996.00 | 02/18/2025 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3871801 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187889104 |
| Principal investigator 1 | Amgen Inc. | $20,334.66 | 02/11/2025 | Non-covered Recipient Entity ONSITE CLINICAL SOLUTIONS,LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246646028 |
| Principal investigator 1 | ABBVIE INC. | $2,286.16 | 02/06/2025 | Non-covered Recipient Entity ACCELLACARE US INC | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202447401 |
| Principal investigator 1 | Eli Lilly and Company | $18,924.00 | 01/27/2025 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187890820 |
| Principal investigator 1 | Amgen Inc. | $25,541.58 | 01/22/2025 | Non-covered Recipient Entity ONSITE CLINICAL SOLUTIONS, LLC SALISBURY | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants with Sjgrens Syndrome With Moderate-to-Severe Symptom State | No dispute reported | 06/30/2026 | 1246646017 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $299.59 | 01/21/2025 | Non-covered Recipient Entity Onsite Clinical Solutions | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment | No dispute reported | 06/30/2026 | 1235994862 |
| Principal investigator 1 | Eli Lilly and Company | $1,679.31 | 01/16/2025 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3871801 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187888796 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,543.50 | 01/15/2025 | Non-covered Recipient Entity ONSITE CLINICAL SOLUTIONS | A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) | No dispute reported | 06/30/2026 | 1190304915 |
| Principal investigator 1 | Eli Lilly and Company | $1,713.76 | 01/13/2025 | Non-covered Recipient Entity ONSITE CLINICAL SOLUTIONS LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | No dispute reported | 06/30/2026 | 1187887104 |
| Principal investigator 1 | Janssen Research & Development, LLC | $412.00 | 01/13/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175249251 |
| Principal investigator 1 | Janssen Research & Development, LLC | $52.00 | 01/13/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175249685 |
| Principal investigator 1 | Janssen Research & Development, LLC | $52.00 | 01/13/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175249933 |
| Principal investigator 1 | Janssen Research & Development, LLC | $185.00 | 01/13/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175250023 |
| Principal investigator 1 | Janssen Research & Development, LLC | $52.00 | 01/13/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175250121 |
| Principal investigator 1 | Janssen Research & Development, LLC | $300.00 | 01/13/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175250213 |
| Principal investigator 1 | Janssen Research & Development, LLC | $52.00 | 01/13/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175250540 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,134.00 | 01/13/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175250589 |
| Principal investigator 1 | Janssen Research & Development, LLC | $52.00 | 01/13/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175250902 |
| Principal investigator 1 | Janssen Research & Development, LLC | $52.00 | 01/13/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175251813 |
| Principal investigator 1 | Janssen Research & Development, LLC | $185.00 | 01/13/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175252552 |
| Principal investigator 1 | Janssen Research & Development, LLC | $52.00 | 01/13/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175252783 |
| Principal investigator 1 | Janssen Research & Development, LLC | $185.00 | 01/13/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175253048 |
| Principal investigator 1 | Janssen Research & Development, LLC | $52.00 | 01/13/2025 | Non-covered Recipient Entity Accellacare Us Inc. | A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) | No dispute reported | 06/30/2026 | 1175253206 |
| Principal investigator 1 | Eli Lilly and Company | $1,535.35 | 01/09/2025 | Non-covered Recipient Entity PIEDMONT MEDICAL RESEARCH ASSOCIATES INC | A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187889110 |
| Principal investigator 1 | Amgen Inc. | $74,055.79 | 01/08/2025 | Non-covered Recipient Entity ONSITE CLINICAL SOLUTIONS, LLC SALISBURY | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246646020 |
| Principal investigator 1 | Eli Lilly and Company | $58,141.00 | 01/07/2025 | Non-covered Recipient Entity ONSITE CLINICAL SOLUTIONS LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | No dispute reported | 06/30/2026 | 1187889890 |